Promentis Pharmaceuticals, Inc. is a pharmaceutical company developing novel compounds for the treatment of schizophrenia and other central nervous system disorders. Anchored in technology licensed from Marquette University and the University of Wisconsin-Milwaukee, Promentisâ drug development efforts are focused on the neurotransmitter glutamate and and imbalances in oxidative stress, key contributors to impaired cortical function linked to multiple CNS disorders. The Companyâs lead compound, SXC-2023, is being developed to treat various psychiatric disorders, with an initial focus on an indication that, despite representing a common disorder affecting millions of patients, has no FDA-approved treatment and a high level of patient ne
